ResMed (RMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $2.08, in-line with the analyst estimate of $2.08. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.22 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Critical One Energy closes second tranche of flow-through placement
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
